Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GV1001 phase 2 trial in mild to moderate Alzheimer's disease
2021-004809-40Phase 2Suspended
- Sponsor
- GemVax & KAEL Co., Ltd.
- Start
- Jul 2022
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tertomotide in Alzheimer's disease (AD) (3 arms), sponsored by GemVax & KAEL Co., Ltd. Primary endpoint: Change from baseline in ADAS-Cog11 score at Week 52. Started Jul 2022; status: suspended.
02
Drugs
tertomotide
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2021-004809-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004809-40.